Bioheart, a company focused on the discovery, development, and commercialization of autologous cell therapies for the treatment of degenerative diseases, has entered into a joint venture with Magnum Cell Therapies.
Magnum Cell Therapies is engaged in providing cutting-edge regenerative medicine therapies to patients suffering from degenerative diseases. The company’s facilities include a state-of-the-art clinic and laboratory located in Honduras.
“We are thrilled to work with the team of specialists and scientists at Magnum. The facilities are top-notch and we are hopeful that Bioheart therapies can help many patients,” Bioheart Chief Science Officer Kristin Comella stated in the news release.
Per the joint-venture agreement, Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum. The two companies will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries.
Bioheart will assume 10 percent ownership of Magnum’s cell therapies. Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism.
For more information, visit www.bioheartinc.com or www.magnumterapiacelular.com
Let us hear your thoughts below: